Literature DB >> 31594518

Major obstacles to doxorubicin therapy: Cardiotoxicity and drug resistance.

Hamdan S Al-Malky1, Sameer E Al Harthi1, Abdel-Moneim M Osman1,2.   

Abstract

BACKGROUND: Doxorubicin is one of the most commonly prescribed and time-tested anticancer drugs. Although being considered as a first line drug in different types of cancers, the two main obstacles to doxorubicin therapy are drug-induced cardiotoxicity and drug resistance.
METHOD: The study utilizes systemic reviews on publications of previous studies obtained from scholarly journal databases including PubMed, Medline, Ebsco Host, Google Scholar, and Cochrane. The study utilizes secondary information obtained from health organizations using filters and keywords to sustain information relevancy. The study utilizes information retrieved from studies captured in the peer-reviewed journals on "doxorubicin-induced cardiotoxicity" and "doxorubicin resistance." DISCUSSION AND
RESULTS: The exact mechanisms of cardiotoxicity are not known; various hypotheses are studied. Doxorubicin can lead to free radical generation in various ways. The commonly proposed underlying mechanisms promoting doxorubicin resistance are the expression of multidrug resistance proteins as well as other causes.
CONCLUSION: In this review, we have described the major obstacles to doxorubicin therapy, doxorubicin-induced cardiotoxicity as well as the mechanisms of cancer drug resistance and in following the treatment failures.

Entities:  

Keywords:  Doxorubicin; cancer; cardiotoxicity; multidrug resistance

Mesh:

Substances:

Year:  2019        PMID: 31594518     DOI: 10.1177/1078155219877931

Source DB:  PubMed          Journal:  J Oncol Pharm Pract        ISSN: 1078-1552            Impact factor:   1.809


  21 in total

1.  HMOX1 silencing prevents doxorubicin-induced cardiomyocyte injury, mitochondrial dysfunction, and ferroptosis by downregulating CTGF.

Authors:  Jia Qian; Wenting Wan; Min Fan
Journal:  Gen Thorac Cardiovasc Surg       Date:  2022-08-25

2.  OSW-1 induces apoptosis and cyto-protective autophagy, and synergizes with chemotherapy on triple negative breast cancer metastasis.

Authors:  Mengling Wu; Qianrui Huang; Mengya Liao; Xuyi Wu; Huizhi Xi; Hongbo Ma; Shanrui Li; Yiwen Zhang; Yong Xia
Journal:  Cell Oncol (Dordr)       Date:  2022-09-26       Impact factor: 7.051

3.  Dye binding assay reveals doxorubicin preference for DNA versus cardiolipin.

Authors:  Colin A Fox; Robert O Ryan
Journal:  Anal Biochem       Date:  2020-02-08       Impact factor: 3.365

4.  Synergistic or Additive Pharmacological Interactions between Magnoflorine and Cisplatin in Human Cancer Cells of Different Histological Origin.

Authors:  Estera Okon; Jarogniew J Luszczki; Wirginia Kukula-Koch; Marta Halasa; Agata Jarzab; Daariimaa Khurelbat; Andrzej Stepulak; Anna Wawruszak
Journal:  Int J Mol Sci       Date:  2020-04-19       Impact factor: 5.923

Review 5.  Polychemotherapy with Curcumin and Doxorubicin via Biological Nanoplatforms: Enhancing Antitumor Activity.

Authors:  Milad Ashrafizadeh; Ali Zarrabi; Farid Hashemi; Amirhossein Zabolian; Hossein Saleki; Morteza Bagherian; Negar Azami; Atefe Kazemzade Bejandi; Kiavash Hushmandi; Hui Li Ang; Pooyan Makvandi; Haroon Khan; Alan Prem Kumar
Journal:  Pharmaceutics       Date:  2020-11-11       Impact factor: 6.321

Review 6.  The Role of HSPB8, a Component of the Chaperone-Assisted Selective Autophagy Machinery, in Cancer.

Authors:  Riccardo Cristofani; Margherita Piccolella; Valeria Crippa; Barbara Tedesco; Marina Montagnani Marelli; Angelo Poletti; Roberta M Moretti
Journal:  Cells       Date:  2021-02-05       Impact factor: 6.600

Review 7.  Hyaluronic Acid-Conjugated Carbon Nanomaterials for Enhanced Tumour Targeting Ability.

Authors:  Oisin Kearns; Adalberto Camisasca; Silvia Giordani
Journal:  Molecules       Date:  2021-12-22       Impact factor: 4.411

8.  Resistance training improves cardiac function and cardiovascular autonomic control in doxorubicin-induced cardiotoxicity.

Authors:  Larissa Andrade de Sá Feitosa; Jéssica Dos Santos Carvalho; Cácia Oliveira Dantas; Diego Santos de Souza; Carla Maria Lins de Vasconcelos; Rodrigo Miguel-Dos-Santos; Sandra Lauton-Santos; Lucindo José Quíntans-Júnior; Márcio Roberto Viana Santos; Valter Joviniano de Santana-Filho; André Sales Barreto
Journal:  Cardiovasc Toxicol       Date:  2021-01-02       Impact factor: 3.231

Review 9.  Ferrocifen Loaded Lipid Nanocapsules: A Promising Anticancer Medication against Multidrug Resistant Tumors.

Authors:  Pierre Idlas; Elise Lepeltier; Gérard Jaouen; Catherine Passirani
Journal:  Cancers (Basel)       Date:  2021-05-11       Impact factor: 6.639

10.  β-Elemene Enhances the Sensitivity of Osteosarcoma Cells to Doxorubicin via Downregulation of Peroxiredoxin-1.

Authors:  Shaochun Zhang; Weichun Guo
Journal:  Onco Targets Ther       Date:  2021-06-03       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.